Braveheart Bio (NASDAQ:BRVE) Stock Keeps “Overweight” Rating at Cantor Fitzgerald

Braveheart Bio (NASDAQ:BRVE)‘s stock had its “overweight” rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $40.00 target price on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 108.22% from the company’s previous close.

A number of other brokerages also recently commented on BRVE. Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Zacks Research upgraded Braveheart Bio to a “hold” rating in a research note on Tuesday, September 1st. The Goldman Sachs Group started coverage on Braveheart Bio in a report on Monday, August 31st. They set a “buy” rating and a $48.00 price target for the company. Jefferies Financial Group started coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $48.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on Braveheart Bio in a research report on Monday, August 31st. They set a “buy” rating and a $45.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.25.

Braveheart Bio Stock Up 2.7%

Shares of Braveheart Bio stock opened at $19.21 on Tuesday. Braveheart Bio has a 52-week low of $17.86 and a 52-week high of $32.00. The stock has a market capitalization of $1.73 billion and a P/E ratio of -7.65. The business has a 50 day moving average price of $24.50.

Braveheart Bio (NASDAQ:BRVE) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($2.26). As a group, analysts predict that Braveheart Bio will post -1.48 EPS for the current year.

Insider Buying and Selling at Braveheart Bio

In related news, Director David Lubner acquired 55,555 shares of Braveheart Bio stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, with a total value of $999,990.00. Following the purchase, the director directly owned 55,555 shares in the company, valued at approximately $999,990. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc acquired 1,940,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the completion of the transaction, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 8,751,942 shares of company stock valued at $157,534,956.

About Braveheart Bio

We are a clinical?stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB?1893, is a next-generation oral small?molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non?obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.